NEOGMEDIUM SIGNALFINANCIAL10-K

Neogen's balance sheet contracted significantly with total assets declining 24% and stockholders' equity falling 34%, though operating cash flow improved substantially.

The material reduction in total assets and equity suggests either major asset disposals, impairments, or dividend distributions that fundamentally resized the company's financial profile. While the substantially improved operating cash flow generation is encouraging and indicates better operational efficiency, investors should understand what drove the balance sheet contraction to assess whether this represents strategic repositioning or financial stress.

Comparing 2025-07-30 vs 2024-07-30View on EDGAR →
FINANCIAL ANALYSIS

Neogen's financial profile shows a tale of two stories - operations improved meaningfully with operating cash flow growing substantially, while the balance sheet contracted significantly with total assets down 24% and stockholders' equity declining 34%. Cash position also weakened by nearly 25%, though current liabilities increased only modestly. The combination suggests potential strategic restructuring or asset optimization, but the scale of balance sheet reduction warrants close investor attention despite the operational cash flow improvements.

FINANCIAL STATEMENT CHANGES
Operating Cash Flow
Cash Flow
+65.2%
$35.3M$58.2M

Operating cash flow surged 65.2% — exceptional cash generation, highest quality earnings signal.

Stockholders Equity
Balance Sheet
-34.1%
$3.1B$2.1B

Equity declined sharply — large losses, buybacks, or write-downs reducing book value significantly.

Cash & Equivalents
Balance Sheet
-24.4%
$170.6M$129.0M

Cash decreased 24.4% — monitor burn rate and upcoming capital needs.

Total Assets
Balance Sheet
-24.3%
$4.5B$3.4B

Total assets contracted 24.3% — asset sales, write-downs, or balance sheet optimization underway.

Current Liabilities
Balance Sheet
+12.8%
$154.3M$174.0M

Current liabilities rose 12.8% — increased short-term obligations, watch current ratio.

Accounts Receivable
Balance Sheet
-11.3%
$173.0M$153.4M

Receivables declined — improved collection efficiency or conservative revenue recognition.

LANGUAGE CHANGES
NEW — 2025-07-30
PRIOR — 2024-07-30
ADDED
The number of outstanding shares of the registrant s Common Stock was 217,205,186 on June 30, 2025.
There are a number of important factors that could cause Neogen s results to differ materially from those indicated by such forward-looking statements, including many factors beyond our control.
Our Food Safety segment consists primarily of diagnostic test kits and complementary products (e.g., culture media) sold to food and animal feed producers and processors to preserve the safety and quality of food to prevent contamination and foodborne illnesses such as foodborne pathogens, spoilage organisms, natural toxins, food allergens, and ruminant by-products.
These products also ensure the general hygiene of the food manufacturing environment.
We also have products to determine food quality and nutritional components.
+7 more — sign up free →
REMOVED
The number of outstanding shares of the registrant s Common Stock was 216,694,486 on June 30, 2024.
There are a number of important factors, including circumstances beyond our control at our transition manufacturing partner, competition, recruitment, retention, dependence on key employees, impact of weather on agriculture and food production, global business disruption caused by the Russia invasion in Ukraine and related sanctions and the conflict between Israel and Hamas, identification and integration of acquisitions, research and development risks, intellectual property protection, government regulation and other risks detailed in item 1A.
Our Food Safety segment consists primarily of diagnostic test kits and complementary products (e.g., culture media) sold to food producers and processors to detect dangerous and/or unintended substances in human food and animal feed, such as foodborne pathogens, spoilage organisms, natural toxins, food allergens, ruminant by-products, meat speciation, drug residues, pesticide residues and general sanitation concerns; as well as food quality and nutritional components.
Our expanding line of food safety products also includes genomics-based diagnostic technology, and advanced software systems that help testers objectively analyze and store, as well as perform analysis on, their results from multiple locations over extended periods.
Our mission is to be the leading company in the development and marketing of solutions for food and animal safety.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →